Please sign in to follow a disease.
Neuren Pharmaceuticals Limited
Clinical trials sponsored by Neuren Pharmaceuticals Limited, explained in plain language.
Biopharmaceutical company developing drugs for neurological disorders.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Hope for rare genetic disorder: new drug trial targets core symptoms
Disease control Recruiting nowThis study tests an oral drug called NNZ-2591 in 160 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition. The drug is compared to a placebo to see if it improves communication and daily function. The trial is double-blind, meaning neither the families no…
Phase 3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC
-
New drug shows promise for rare genetic disorder in kids
Disease control Recruiting nowThis phase 3 study is testing an oral drug called NNZ-2591 in 180 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition that causes developmental delays and other challenges. The main goal is to see if the drug is safe and tolerable over the long term. Res…
Phase 3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Sep 21, 2026 18:00 UTC